

# Pre-clinical study of ASO drug for treating Parkinson's disease

**HLB Neurotobe**



HLB NeuroTobe

NEUROLOGY	Preclinical
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Parkinson's disease
Target	****
MoA(Mechanism of Action)	NT-3, an Antisense Oligonucleotide (ASO) designed to target ***mRNA, effectively reduces aberrant neuronal firing, leading to a rapid alleviation of Parkinsonian motor symptoms and concurrent protection against further degeneration of dopamine neurons.
Competitiveness	NT-3 exhibits dual mechanisms of action, preventing both the onset of Parkinson's symptoms and the demise of dopaminergic neurons.
Development Stage	Preclinical
Route of Administration	Administration via the intrathecal route at 3 to 4-month intervals.

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*